Skip to main content

IHE

ETF

IHE

ETF
—
—

Performance overview

IHE Price
Price Chart

Forward-looking statistics

Beta
0.62
Risk
20.74%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

Fund info

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

Investing methodUnknown
DiversifiedNo
Expense ratio0.39%
Asset classEquities

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$1.17
Revenue per share—
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$4M
Put-call ratioN/A

Macro factor sensitivity

Growth+1.1
Credit+2.1
Liquidity-0.2
Inflation-1.3
Commodities0.0
Interest Rates-0.9

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayMarch 18, 2025

News

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

The iShares U.S. Pharmaceuticals ETF (IHE) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks Investment Research (July 1, 2025)
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.

Benzinga (May 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free